Benzinga Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026
FDA extends Ascendis' TransCon CNP review to Feb. 28, 2026, after new data submission related to post-marketing study requirements. read more
FDA extends Ascendis' TransCon CNP review to Feb. 28, 2026, after new data submission related to post-marketing study requirements. read more